Neogenix Oncology Receives Notice of Allowance for Its 16C3 Antibody Patent Application and Expands Patent Portfolio

GREAT NECK, N.Y.--(BUSINESS WIRE)-- Neogenix Oncology announced today that the U.S. Patent and Trade Mark Office (USPTO) has issued a Notice of Allowance for a patent application related to its 16C3 antibody. Discovered and developed by Neogenix Oncology, this antibody appears to have anti-tumor activity for both pancreatic and colorectal tumors, and may have both therapeutic and diagnostic utility. The antibody may have activity in other tumors as well, which the company will explore at such time as it prepares a pre-IND package for FDA review and designs a clinical trial for the 16C3 antibody. This patent will cover the third antibody line held by the Company.

“This marks yet another important step forward in our efforts to discover and develop novel new antibodies for the diagnosis and treatment of a range of cancers. We have been impressed with the properties of 16C3 as it appears to be a potent antibody, and with a unique target. Although it acts through the ADCC mechanism for tumor killing, it appears to have additional mechanisms for tumor kill, making it a very exciting antibody. We believe that 16C3 has the potential to become an important new diagnostic and therapeutic tool in the fight against pancreatic and colorectal cancer.” said Neogenix President and Chief Executive Officer, Philip M. Arlen, MD.

The USPTO has previously granted a patent for the company’s lead monoclonal antibody NPC-1C (ensituximab), and claims in a related divisional patent application have been allowed relating to the genes encoding the novel molecular aspects of NPC-1C.

Additional information regarding Neogenix Oncology can be found at www.neogenix.com.

About Neogenix Oncology

Neogenix Oncology is a development stage biotechnology company focused on developing and commercializing therapeutic and diagnostic products for the early detection and treatment of pancreatic, colorectal, lung, cervical, ovarian, prostate, and other cancers. The company’s portfolio includes monoclonal antibodies that are designed to be specific to cancer cells by recognizing epitopes that are tumor specific, that is, found on cancer cells, but not normal cells. Founded in late 2003 and headquartered in Great Neck, NY, the company conducts its research and development work in its laboratories in Rockville, MD.

Forward Looking Statements Certain statements contained in this release are forward-looking statements that relate to future events. These statements are based on current expectations only and are subject to known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from any future results express or implied by such forward-looking statements, including those risk factors discussed in the Form 10 of Neogenix Oncology. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

Press:
RMT PR Management
RoseMarie Terenzio, 212-414-1909
(c) 917-913-7226
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Other Health  Research  Other Science  Science  General Health

MEDIA:

Suggested Articles

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

Creating new, successful central nervous system drugs is tough, and Lundbeck knows this better than most after canning an internal CNS effort.

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.